1535212-06-6

Basic information

• Product Name: (33R,34S,35S,91R,92R,5S,E)-5-(tert-butyl)-34-ethyl-14,14-difluoro-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxylic acid
• Synonyms: (33R,34S,35S,91R,92R,5S,E)-5-(tert-butyl)-34-ethyl-14,14-difluoro-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxylic acid
• CAS NO: 1535212-06-6
• Molecular Formula: C₃₁H₄₀F₂N₄O₇
• Molecular Weight: 618.67
• Mol File: 1535212-06-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (33R,34S,35S,91R,92R,5S,E)-5-(tert-butyl)-34-ethyl-14,14-difluoro-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (33R,34S,35S,91R,92R,5S,E)-5-(tert-butyl)-34-ethyl-14,14-difluoro-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxylic acid(1535212-06-6)
• EPA Substance Registry System: (33R,34S,35S,91R,92R,5S,E)-5-(tert-butyl)-34-ethyl-14,14-difluoro-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxylic acid(1535212-06-6)

Safety Data

• Hazardous Substances Data: 1535212-06-6(Hazardous Substances Data)

Usage

General Description

The chemical "(33R,34S,35S,91R,92R,5S,E)-5-(tert-butyl)-34-ethyl-14,14-difluoro-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxylic acid" is a complex compound with a cyclopropane ring and a quinoxaline structure. The compound contains various substituents, including a tert-butyl group, an ethyl group, and a difluoro-17-methoxy group. It also contains a pyrrolidine ring and a cyclopropanecarboxylic acid group. This chemical has potential applications in pharmaceuticals and may exhibit biological activity due to its unique structure and functional groups.

Upstream product

• 1026200-25-8 methyl 3-methyl-N-({[(1R,2R)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valinate 
• 1026200-27-0 3-methyl-N-({[(1R,2R)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valine 
• 1535210-59-3 C₁₄H₂₃NO₅ 
• 1535210-60-6 C₁₄H₂₅NO₅ 
• 1535210-61-7 C₁₄H₂₃NO₄ 
• 1294512-26-7 ethyl 3,3-difluoro-2-oxopent-4-enoate 
• 1535210-94-6 C₁₂H₉ClF₂N₂O 
• 1535212-03-3 C₃₇H₅₀F₂N₄O₇ 
• 1535212-05-5 C₃₅H₄₈F₂N₄O₇ 
• 20859-02-3 L-tert-Leucine 

Downstream Products

• 1535212-07-7 (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1 R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,1 0,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide 

Relevant articles and documents

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi

Treatment of hepatitis C virus (HCV) infection has been historically challenging due the high viral genetic complexity wherein there are eight distinct genotypes and at least 86 viral subtypes. While HCV NS3/4A protease inhibitors are an established treatment option for genotype 1 infection, limited coverage of genotypes 2 and/or 3 combined with serum alanine transaminase (ALT) elevations for some compounds has limited the broad utility of this therapeutic class. Our discovery efforts were focused on identifying an NS3/4A protease inhibitor with pan-genotypic antiviral activity, improved coverage of resistance associated substitutions, and a decreased risk of hepatotoxicity. Towards this goal, distinct interactions with the conserved catalytic triad of the NS3/4A protease were identified that improved genotype 3 antiviral activity. We further discovered that protein adduct formation strongly correlated with clinical ALT elevation for this therapeutic class. Improving metabolic stability and decreasing protein adduct formation through structural modifications ultimately resulted in voxilaprevir. Voxilaprevir, in combination with sofosbuvir and velpatasvir, has demonstrated pan-genotypic antiviral clinical activity. Furthermore, hepatotoxicity was not observed in Phase 3 clinical trials with voxilaprevir, consistent with our design strategy. Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) is now an approved pan-genotypic treatment option for the most difficult-to-cure individuals who have previously failed direct acting antiviral therapy.

CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND

Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetrade